Streetbeat News

Analyst Ratings

PTCT

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on PTC Therapeutics (NASDAQ:PTCT) but has reduced the price target from $27 to $22.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:29 pm

LEVI

Levi Strauss & Co (NYSE:LEVI) shares fell in premarket trading after Q4 results. Despite softer revenues and job cuts, an earnings beat was reported due to higher gross margin expansion and a lower tax rate. Analyst Dana Telsey of Telsey Advisory Group maintained an Outperform rating and raised the price target from $16 to $18. The company faces headwinds from the Denizen exit and other factors but expects low single-digit revenue growth for fiscal 2024. All regions showed growth for the first time since 2Q22.

Portfolio Pulse from Priya Nigam

January 26, 2024 | 3:28 pm

AMSC

Roth MKM analyst Justin Clare has maintained a Buy rating on American Superconductor (NASDAQ:AMSC) and increased the price target from $10 to $15.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:27 pm

VERA

Vera Therapeutics' stock price increased following the release of positive data from its Phase 2b ORIGIN clinical trial. Additionally, Raymond James upgraded Vera Therapeutics to Strong Buy.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:25 pm

OSIS

Roth MKM analyst Jeff Martin has reaffirmed a Buy rating on OSI Systems (NASDAQ:OSIS) and increased the price target from $165 to $169.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:24 pm

HUM

RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Humana (NYSE:HUM) but has reduced the price target from $507 to $415.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:23 pm

HXL

RBC Capital analyst Ken Herbert has reiterated an Outperform rating on Hexcel (NYSE:HXL) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:18 pm

SNAP

Roth MKM analyst Rohit Kulkarni has maintained a Neutral rating on Snap Inc. (NYSE:SNAP) but increased the price target from $10 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:17 pm

BTCUSD

Macro analyst Lyn Alden rated Bitcoin's health as A-, citing its 'highly investable' status based on five metrics: market capitalization and liquidity, increasing convertibility, the Lindy effect indicating longevity, improving user experience, and resistance to being banned. Alden's positive outlook is contingent on Bitcoin's price continuing to make higher highs and lows over several years amidst rising global liquidity.

Portfolio Pulse from Ivan Crnogatić

January 26, 2024 | 3:14 pm

FICO

RBC Capital analyst Ashish Sabadra has reiterated a 'Sector Perform' rating on Fair Isaac (NYSE:FICO), with a maintained price target of $1350.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:14 pm